Give us a sequence, and we'll take care of everything else

The RNA Foundry works with researchers & biotechs to take their new mRNA biomedicines to clinical trial readiness end-to-end using PopVax's mRNA-LNP and GMP platforms, starting with just the RNA sequence and ending with a Phase I-ready GMP batch of clinical doses, in 2 years.

Get Started

Our Services

mRNA Engineering

Design mRNA molecules tailored for your application
Optimize untranslated regions (UTRs) and signal sequences
Enhance translation efficiency and stability
Improve localization and functional protein expression

Advanced Lipid Innovations

Over 600 ionizable lipids designed in-house
80+ lipids successfully tested in vivo
Lead LNP formulation matches market leaders in rodents
Ensures safe and effective mRNA vaccine delivery

Custom mRNA-LNP Formulations

Formulate mRNA-LNP using your provided sequence
Apply proprietary ionizable lipid technology
Deliver samples for critical functional validation

Scale Up

Expert process development for mRNA-LNP formulations
Optimize yield, purity, and functionality
Ensure high-quality, scalable production

End-to-End GMP Manufacturing

Fully integrated GMP facility with ISO 7/8 cleanrooms
End-to-end production: pDNA synthesis to LNP encapsulation
Facility designed to meet FDA regulatory expectations

All Pre-Clinical Studies

Design and conduct toxicology and biodistribution studies
Collaborate with trusted CROs for pre-clinical testing
Support your team's functional assay needs

About Us

RNA Foundry is a PopVax initiative!

PopVax is a Gates Foundation-funded biotech company, focused on developing broadly protective mRNA vaccines through generative AI-driven computational protein design. Our team of 70+ experts works at the RNA Foundry, our integrated R&D and cGMP-clinical production facility in Hyderabad.

PopVax is committed to advancing innovative vaccines to address global infectious diseases and improve public health.

Timeline & Cost

Our end-to-end service takes approximately 2 years to deliver a Phase I-ready GMP batch of clinical doses.

Service Fee

$10 million for end-to-end service, covering everything from sequence design to GMP manufacturing.

Royalty

4% royalty on net sales for use of our platform.

Milestones

Additional milestone payments tied to key achievements, such as IND approval and Phase I completion.